Trump fires Fed's Cook, Musk sues Apple and OpenAI, Netflix's theatrical run and more in Morning Squawk

President Trump's unprecedented firing of Federal Reserve Governor Lisa Cook, contested on legal grounds and intensifying political pressure for rate cuts, prompted a steepening of the U.S. Treasury yield curve. Concurrently, Eli Lilly shares rose following positive late-stage trial results for its oral weight-loss drug, orforglipron, positioning it for regulatory submission and significant entry into the booming GLP-1 market. Separately, Elon Musk's xAI sued OpenAI and Apple, alleging an anticompetitive scheme within the AI sector, escalating his ongoing disputes with both tech giants.

Analysis

The market is contending with a significant increase in monetary policy uncertainty following the unprecedented firing of Federal Reserve Governor Lisa Cook by the President. This action, justified 'for cause' but legally contested, is viewed as an escalation of political pressure on the central bank to lower interest rates and has already manifested in a steepening of the U.S. Treasury yield curve. In the corporate sphere, Eli Lilly (LLY) has provided a major positive catalyst, with shares rising approximately 2% pre-market after announcing successful late-stage trial results for its oral weight-loss drug, orforglipron. This positions the company to seek regulatory approval for a needle-free alternative in the high-growth GLP-1 market, with a potential global launch targeted for next year. Concurrently, the artificial intelligence sector faces new legal friction as Elon Musk's xAI has sued Apple (AAPL) and OpenAI, alleging an 'anticompetitive scheme' that introduces a litigation overhang for Apple's AI strategy. Finally, while Netflix's (NFLX) theatrical release of 'KPop Demon Hunters' generated a 'sizable haul,' industry sentiment suggests this is unlikely to signal a fundamental shift in its distribution strategy.

Key Decisions for Investors

• Investors should brace for heightened volatility in fixed income markets and monitor the legal proceedings regarding the Fed governor, as the increased politicization of the central bank injects significant uncertainty into the future path of interest rates.
• The positive trial data for Eli Lilly's oral drug orforglipron solidifies its leadership in the GLP-1 market, warranting a re-evaluation of its long-term growth forecasts and competitive standing against peers.
• The xAI lawsuit against Apple introduces a new legal and reputational risk to its AI initiatives, and positions in AAPL should be monitored for any developments that could impact its competitive positioning in this critical growth segment.
• While Netflix's theatrical experiment is a minor positive, investors should not interpret it as a strategic pivot and should continue to focus on core subscriber and revenue growth metrics for the streaming business.